

Patellofemoral knee arthroplasty

Massimo Berruto, Daniele Tradati, Paolo Ferrua, Alessio Maione, Eva Usellini

SSD Chirurgia Articolare del Ginocchio, Istituto Ortopedico Gaetano Pini, Milan, Italy

Contributions: (I) Conception and design: All authors; (II) Administrative support: None; (III) Provision of study materials or patients: All Authors; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Massimo Berruto. SSD Chirurgia Articolare del Ginocchio, Istituto Ortopedico Gaetano Pini, Piazza A. Cardinal Ferrari 1 Milan Italy. Email: massimo.berruto@fastwebnet.it.

Abstract: Patellofemoral osteoarthritis (OA) is a common degenerative disease present in 10%-25% of patients presenting symptomatic knee OA. It can be found isolated or secondary to inflammatory joint diseases, patellar fractures and patellar instability. Anatomical abnormalities such as patella alta, altered patellar tilt and trochlear dysplasia can be identified as predisposing factors in patellofemoral OA etiopathology. In symptomatic patients with advanced stages isolated patellofemoral OA unicompartmental patellofemoral arthroplasty (PFA) is nowadays considered as the gold standard treatment. First reported by McKeever in 1955, PFA underwent a constant evolution in term of design and surgical techniques. Two kinds of prosthetic design are now available: *resurfacing* (so called inlay), in which the native trochlear shape and orientation remain unchanged with high bone preservation, and *trochlear cutting* (so called onlay) characterized by a wider asymmetrical trochlea with a higher level of patellar constraint. The success of replacement depends mainly on good patient selection and respect of relative and absolute contraindications. The outcomes are heterogeneous: recent studies about inlay generation showed a high revision rate (28%) at 6 years of follow-up. Onlay implants demonstrated a greater percentage of good to excellent results and survivorship, albeit inferior if compared to total knee arthroplasty. Early failure may be correlated to unexplained pain, progression of osteoarthritic process to femorotibial compartments and patellar maltracking, and late failure main cause remains progression of OA, followed by aseptic loosening and residual pain. In conclusion there is still no consensus for PFA indications and further long term and randomized studies are needed to assess the clinical benefits and long-term survivorship of this kind of implant.

Keywords: Patellofemoral replacement; arthroplasty; patellofemoral osteoarthritis (OA)

Received: 28 February 2017; Accepted: 26 May 2017; Published: 09 August 2017.

doi: 10.21037/aoj.2017.07.09

View this article at: <http://dx.doi.org/10.21037/aoj.2017.07.09>

Introduction

Isolated patellofemoral Joint Osteoarthritis (PFOA) is a common degenerative disease involving 10–25% of patients with symptomatic knee osteoarthritis (OA) (1-4), Noble *et al.* reported an incidence of 79% in a cadaveric study on patients aged over 65 years (5). PFOA is by far more common than isolated medial or lateral femorotibial osteoarthritis (FTOA). An association with symptomatic medial FTOA was identified in 12% of patients (3). The lateral facet is more frequently involved than the medial one

(92% *vs.* 8%) (6).

McAlindon *et al.* observed an augmented prevalence in females for isolated anterior compartment degeneration (24% *vs.* 11%) (2) but a recent systematic review and meta-analysis revealed comparable prevalence in both sexes (27% *vs.* 26%) (4). This lack of consensus can be expression of the variable entity of symptoms and by the fact that the progression of the degenerative process is typically slow (7). In presence of symptomatic high grade PFOA prosthetic treatment is generally considered

as the gold standard of treatment. Despite this general consideration there is still a lack of consensus about the role of patellofemoral arthroplasty (PFA). The results reported in literature based on first generation PFA lead some authors to consider this procedure as a bridge before total knee replacement or even to contraindicate PFA in favor of total knee arthroplasty (TKA) (8,9). Nevertheless, improvement in new generation prosthetic design and surgical techniques demonstrated more consistent clinical results and good mid-term implant survivorship bringing more surgeons to consider this procedure as safe and effective in treating isolated PFOA (10).

Aetiology and classification

PFOA can recognize different aetiologies such as previous recurrent patellar dislocation, cartilage lesions, inflammatory diseases and patellar fractures sequelae. Dejour and Allain in a multicentric study identified four groups possibly leading to PFOA: 8% were concomitant to inflammatory diseases such as chondrocalcinosis, 9% were associated to previous patellar fracture, a large group (33%) was associated to previous patellofemoral dislocations and finally 49% were considered as primary (idiopathic) (7).

The most common classification system is the one described by Iwano *et al.* (6), based on axial view X-rays. Four stages are described:

- ❖ Stage 1: patellofemoral remodelling;
- ❖ Stage 2: reduction on joint line less than 3 mm;
- ❖ Stage 3: reduction of joint line more than 3 mm;
- ❖ Stage 4: bone on bone facet.

Predisposing factors

Anatomical abnormalities are described as a potential predisposing factor in developing of PFOA. The most common abnormalities are: patella alta, excessive patellar tilt, off-set and trochlear dysplasia (11-13). These considerations were confirmed by Dejour and Allain who observed radiological signs of trochlear dysplasia in 78% of isolated PFOA (7). One of the possible explanations is that supratrochlear spur, identifiable in type B and D trochlear dysplasia (14), could increase patellofemoral joint load in flexion performing a so called "Anti-Maquet effect". A correlation between patella dysplasia and PFOA was also observed, with PFOA occurring more frequently in Wiberg type 2 patellas (7,15).

Relationships between patellofemoral disorders in young

population can be correlated with an increased risk of knee OA changes (16,17). Recurrent patellofemoral dislocation was recognized as one on the main causes by Conchie *et al.* reporting an increased risk (adjust OR of 3.2) of developing PFOA in presence of previous patellar dislocations. These data were similar to the one observed in patients who underwent previous knee surgeries. (adjust OR of 3.5) (16).

In a recent cohort study, including 609 patients, Sanders *et al.* observed an even higher risk of PFOA in subjects who experienced a lateral patellar dislocation (HR 7.8; 95% CI, 3.9–17.6; P<0.001) (17).

Treatment

Being most of isolated PFOA symptoms well tolerated, and knowing that clinical and radiological progression can be very low, the treatment of PFOA is mainly conservative (7).

In patients not responding to conservative treatment (rehabilitation program, weight reduction, oral pain killers or intrarticular viscosupplementation) (18-21), surgical treatment is a viable option in order to provide pain relief and restore PF joint function.

In treatment of PFOA many surgical procedures have been described, reporting variable results, varying from Lateral release (22), Anterior Tibial Tuberosity (ATT) osteotomy (23,24), reparative surgery of cartilage lesions (25), patellectomy (26), PFA (27-30) and TKA (8,9,31,32).

In advanced stage PFOA most of the authors advocate prosthetic solutions which include PFA and TKA. In the recent past PFA is gaining more and more popularity considering the promising results of new generation implants and less invasive surgical technique when compared to TKA.

Patellofemoral joint arthroplasty

McKeever first reported in 1955 the use of a screw-on Vitallium patellar implant in alternative to patellectomy, historically associated to unsuccessful clinical results (33). Despite having short-term good results, also confirmed by Levitt (34) and Vermeulen *et al.* (35), early failure of McKeever prosthesis was reported due to the rapid native trochlear wear (36). In 1979 a new generation implant, the Richards PFA, was presented but results were inconsistent (37). In the past few years the concept of PFA has been constantly evolving with introduction of new generation implants and surgical techniques.

Resurfacing implants

This kind of implants is meant to replace worn cartilage laying on subchondral bone. Being based on pre-existing anatomy of the native trochlea, anatomical parameters such as shape or orientation remain unchanged when using this kind of implants, the resurfacing implants are also defined as “Inlay”. This type of design allows a highly conservative bone preparation, flush with native surrounding cartilage and parallel to the original trochlear inclination. The mediolateral coverage of the trochlea is limited and the proximal extension of the component is contained by the trochlear cartilage surface.

Implant positioning highly depends on underlying trochlear anatomy, therefore the presence of trochlear dysplasia can lead to a greater risk of components malpositioning (in particular excessive internal-rotation) possible leading to instability or maltracking. In addition surgical technique mainly relies on free hand preparation, leading to reduced reproducibility and accuracy in implants positioning. Associated surgical procedures are necessary in presence of excessive patella height and TT-TG (Tibial Tuberosity Tibial Groove) to achieve a proper patellar tracking.

Trochlear cutting implants

In 1990s the poor clinical results of first generation implants, mainly due to patellofemoral maltracking and instability, lead to the development of the second generation patellofemoral prosthesis, the so-called “Onlay design” These implants are based on TKA anterior flange, flush with the anterior femoral cortex, reducing the risk of potential impingement with residual trochlear bone (38,39).

Second generations implants are characterized by a wider trochlea in mediolateral size, extending more proximally than the original cartilage, a less obtuse sagittal radius of curvature, a higher level of patellar constraint and a high asymmetrical lateral flange, in order to resist lateral dislocation quadriceps force (40).

The surgical technique is more reproducible and adaptable to the patient’s anatomic characteristics, allowing a better rotational control of the femoral component whatever the pre-existing anatomy, therefore additional extensor mechanism procedures are no longer systematically required in order to obtain implant stability.

These advancements in components design lead to reduction of snapping, catching and popping, allowing free

transverse movement in full extension.

Indications

The success of the surgical procedure heavily depends upon patient selection. Most of the authors agree on performing PFA in isolated PFOA, whatever the aetiology, greater than Iwano stage 2. Another typical indication is failure of previous surgeries such as ATT osteotomy or cartilage regeneration procedures. A BMI higher than 30 represents, according to van Jonbergen *et al.* (41), a relative contraindication. These findings are supported by Dahm *et al.* who reported significantly lower ($P>0.03$) KSS improvement in this category of patients despite not finding any significative difference in pain, knee flexion, satisfaction and progression of tibiofemoral joint OA (27).

Observing that progression of Osteoarthritis to the non-replaced tibiofemoral compartments is the main cause of revision in PFOA, presence of OA great than Kellgren-Lawrence grade 1 in medial or lateral compartment, excessive valgus or varus and history of meniscal surgery represent an important contraindication. Other absolute contraindications are Complex Regional Pain Syndrome, Inflammatory diseases such as, chondrocalcinosis and rheumatoid arthritis, active infections and psychogenic anterior knee pain (42-44).

Outcomes

PFA is considered to have several theoretical advantages if compared to TKA, such as good bone-stock and soft-tissue preservation (31), reduced blood loss and hospitalization time (33) and more physiological knee kinematics potentially allowing faster recovery and better clinical outcomes (*Table 1*).

Despite these considerations about re-creating kinematics close to physiology, the number of biomechanical studies investigating this aspect is limited and results are heterogeneous (40,45,56).

Resurfacing implants

A large number of studies are available for first generation Inlay-design although heterogeneous in implanted prosthetic model, inclusion criteria and quality. Hoogervorst *et al.* reported good to excellent results in satisfaction score in 90% of patients, a survival rate of 73% at 10 years, with a TKA conversion rate of 21% at 5.5 years, mainly due to

Table 1 Clinical results of inlay-onlay design patellofemoral arthroplasty

Study [year]	Implant design	Prosthetic model	No. of implants	Mean age (yrs)	Mean FU (yrs)	Good/Excellent results (%)	Failure/revision (%)
Blazina et al. (45) [1979]	Inlay	Richards type I and II	57	39 [19-81]	2 (0.6-3.5)	/	35
Kooijman et al. (46) [2003]	Inlay	Richards type II	45	50 [20-77]	17 [15-21]	86	22
van Jonbergen et al. (41) [2010]	Inlay	Richards type II	185	52 (/)	13.3 (2-30.6)	/	25
Cartier et al. (47) [2005]	Inlay	Richards II and III	79	60 [36-81]	10 [6-16]	77	25
Argenson et al. (29) [2005]	Inlay	Autocentric	66	57 [21-82]	16 [12-20]	/	42
Tauro et al. (48) [2001]	Inlay	Lubinus	62	66 [50-87]	7.5 [5-10]	45	28
Lonner et al. (49) [2004]	Inlay	Lubinus	30	38 [34-51]	4 [2-6]	84	33
Hoogervorst et al. (28) [2015]	Inlay	Richards type II	33	47.4 [32-81]	9.7 (2.2-18.8)	90	36
Feucht et al. (10) [2015]	Inlay	HemiCAP Wave	15	48 [40-56]	2.2 (1.3-3.1)	/	13
Laurson et al. (50) [2016]	Inlay	HemiCAP Wave	18	51 [28-70]	1.5 [1-2]	/	28
Lonner et al. (49) [2004]	Onlay	Avon	25	44 [28-59]	0.5 (0.1-1)	96	None
Ackroyd et al. (51) [2007]	Onlay	Avon	109	68 [46-86]	5.2 [5-8]	80	3.60
Odumenya et al. (30) [2010]	Onlay	Avon	50	66 [42-88]	5.3(2.1-10.2)	/	4
Mont et al. (52) [2012]	Onlay	Avon	43	29 [27-67]	7 [4-8]	/	12
Halai et al. (12) [2016]	Onlay	Femoro-Patella Vialla (FPV)	41	65 [41-81]	3.2 (2-4.5)	78	2.40
Al-Hadithy et al. (53) [2014]	Onlay	Femoro-Patella Vialla (FPV)	49	62.2 [39-86]	3.4 (1-5.8)	/	3
Feucht et al. (10) [2015]	Onlay	Journey	15	49 [41-57]	2.2 (1.3-3.1)	/	13
Sarda et al. (54) [2011]	Onlay	Avon	44	/	4.5 [3-6]	85	4.60
Konan et al. (55) [2016]	Onlay	Avon	47	57 [37-69]	7.1 [5-11]	100	3.90

TFOA progression (71% of cases) (28). These data appear to be comparable to the ones reported by Van Jonbergen *et al.* (84% survival-rate at 10 years) (41) and Cartier *et al.* (75% survival rate at 10 years) (47).

Considering the 90% survival rate at 10 years, set as acceptable minimal threshold by ODEP benchmark for prosthetic implants, was not reached.

The author stressed the importance of carefully excluding TFOA, defined as the main cause of failure, in order to reduce the re-intervention rate after PFA (28).

Good to excellent long term results at a mean FU of 17.8 ± 0.8 years were reported by Kooijman *et al.* showing a 98% survival rate and a satisfaction rate of 86% (46). These positive data are contrasting with the one observed by Argenson *et al.* reporting a cumulative survival rate of only 58% at 16 years FU (29).

Regarding new generation Inlay prosthesis Feucht *et al.* reported in a short-term matched-pair comparison study (mean FU 24 months) with Onlay implants, similar result in clinical scores ($P > 0.05$) and implant survivorship but a slower TFOA progression in the Inlay group (10).

Comparable results about the same implant have been recently reported by Cotic *et al.*, in the authors' view the more physiological placement of the Inlay prosthesis could reduce the risk of patellar overstuffing leading to a lower progression of TFOA (57).

According to these authors these so called "second generation implants" could increase patellar stability, without altering soft tissue tension and reducing the risk of patellar overstuffing (58,59). A recent mid-term study by Laursen *et al.*, based on similar prosthetic design, reported a high revision rate (28%) at 6 years FU, leading the author to consider this kind of implants as a temporary solution, with good to excellent results in short-term period for younger patients ineligible for TKA (50). There is a need of long-term clinical studies in order to better define clinical results and revision rate of new Inlay prosthesis design which could diverge from the first generation one, even in consideration of the wider inclusion criteria used in the older studies including patients with initial signs of TFOA.

Trochlear cutting implants

The outcomes of Onlay design Implants were discussed by several clinical studies.

Halai *et al.* reported results about 31 patients (mean age 65 years) affected by idiopathic PFOA with a mean follow-up of 3.2 years, describing 78% of patient satisfaction with a

97.6% survival rate (12).

Al-Hadithy *et al.* reported about 41 patients affected by isolated PFOA, evaluated at mean follow-up of 37 months, with improvement of Oxford Knee Score (from 19.7 to 37.7) and a 97% survival rate (53).

These results seem comparable to those found in prior studies in which the percentage of good to excellent results was superior to 90% (30,60).

A slightly lower survivorship rate (82%) was reported by Mont *et al.* on 37 patients (mean age 49 years) and mean follow-up of 7 years (52). Outcomes of PFA in post-traumatic PFOA were described by Konan *et al.* reporting results on 51 patients (mean age 57 years). At the mean FU of 7.1 years the median Oxford Knee Score was 38 with excellent reported pain relief and functional outcomes. Survivorship was 96.1% and only two revisions were reported (one for residual pain and one for TFOA progression) (57).

In patients presenting PFOA variably associated to medial and/or lateral compartment OA and with intact ligaments, some authors suggest the combinations of PFA with unicompartmental knee arthroplasty (UKA). Data in literature reporting clinical results of these procedures combined are few, even though outcomes seem to be promising (61-64).

Further long-term high quality studies are needed to assess the clinical benefits of this implant association, even in consideration of the good results of TKA in treatment of PFOA (Table 2).

Complications

A high failure risk and complication rate in PFA was previously reported although nowadays improvement in prosthetic design and careful patient selection lead to better clinical results, with a significant decrease in complications rate.

A recent systematic review by van der List *et al.*, combining cohort studies and registries, analysed the main causes of failure in PFA.

Early failure was most commonly due to unexplained pain (31%), OA progression (24%) and patellar maltracking (14%) (69). The reason of unexplained pain can be found in both progression of OA or a specific prosthetic design issues (70-72).

The most common reasons of late failure are represented by OA progression (46%), aseptic loosening (18%) and pain (9%) (69).

Table 2 Clinical results of total knee arthroplasty in treatment of isolated patellofemoral osteoarthritis

Study (year)	No. of implants	Age in years (range)	Mean FU in years (range)	Results
Laskin <i>et al.</i> (65) [1999]	48	67 [54–85]	7.4 (3-9.5)	Survival rate 98%; mean AKS improvement 71 → 96
Thompson <i>et al.</i> (9) [2001]	33	73 [58–89]	1.7 (1-3.3)	No patellar resurfacing; at last FU 21 knees pain free, 12 knees mid discomfort
Parvizi <i>et al.</i> (66) [2001]	31	70 [47–85]	5.2 [2–12]	Survival rate 94%, mean KSS improvement 53.6 → 88.9, mild pain in 5 knees, moderate pain in one knee
Mont <i>et al.</i> (8) [2002]	30	73	6.7 [4–11]	97% good/excellent results; mean KSS improvement 50 → 93%; 1 poor result due to patellar tendon rupture
Dalury <i>et al.</i> (67) [2005]	33	70.2 [54–81]	5.2 (3.8-8.4)	Mean KSS improvement 62 → 96
Meding <i>et al.</i> (68) [2007]	33	62	6.2 [2–12]	Mean KSS improvement 49 → 88; 88% patients reported minimal or no pain; 6% residual anterior knee pain; no difference between TKA for TFOA
Dahm <i>et al.</i> (32) [2010]	22	69 [44–83]	27 [24–33]	TKA vs. PFA no difference in pain but in PFA group better improvement in function and activity level

An interesting finding is the association between OA progression and the indication to PFA: Argenson *et al.* reported a higher incidence in patients with primary PFOA (44%) than post-traumatic OA (17%) and patellar instability (14%) (29). Similar conclusions were proposed by Nicol *et al.* (73) and Dahm *et al.* (27). Other conditions, such as Infections and implant loosening, play nowadays a minor role in implants failure (69).

A meta-analysis by Monk *et al.* (74) reported decreasing in PFA complications rate in recent implants design (from 39% to 14%) although still remaining higher than TKA (7%); the authors focused on the geometrical design of the prosthesis therefore attributing the most of the failure mechanism to a mechanical problem (instability, loosening, malalignment). A careful analysis of the risk-benefit rate should be accomplished by the surgeon, in accordance with the patient, in order to maximize the clinical results reducing the risk of further surgical revision.

Conclusions

PFJA has been considered an alternative to TKA in patients with advanced symptomatic isolated OA.

In the last decades new prosthetic design, materials and surgical techniques were developed changing radically the vision about patellofemoral replacement. Literature reports heterogeneous evidences of clinical results, from the excellent long-term follow-up outcomes described by Kooijman (mean FU 17.8±0.8 years, 98% survival rate and 86% satisfaction rate) (46) to the poorer ones reported by Argenson *et al.* (mean FU 16 years, cumulative survival 58%) (29). Despite the high complication and revision rate observed in the first generation implants, the last clinical available studies show a trend towards improvement, reporting a PFA complication rate decreasing from 39% to 14% even though still remaining higher than TKA (7%) (74).

Nowadays there is still no consensus on the ideal trochlear design, even in consideration of the new generation Inlay models which showed similar result in clinical scores (P>0.05) and implant survivorship over Onlay models (10,52). Careful patients selection as been highlighted as the key of success but there is still no agreement over precise guidelines for indicating PFA. Further high level long term and randomized controlled studies are needed to confirm good results of PFA. Surgeons have to weigh the long-term success rate of TKA with the good clinical results in short-midterm FU of PFA, which

also do not interfere with further conversion to TKA (75).

Acknowledgements

None.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

References

- Davies AP, Vince AS, Shepstone L, et al. The radiologic prevalence of patellofemoral osteoarthritis. *Clin Orthop Relat Res* 2002;(402):206-12.
- McAlindon TE, Snow S, Cooper C, et al. Radiographic patterns of osteoarthritis of the knee joint in the community: the importance of the patellofemoral joint. *Ann Rheum Dis* 1992;51:844-9.
- Duncan RC, Hay EM, Saklatvala J, et al. Prevalence of radiographic osteoarthritis--it all depends on your point of view. *Rheumatology (Oxford)* 2006;45:757-60.
- Kobayashi S, Pappas E, Franssen M, et al. The prevalence of patellofemoral osteoarthritis: a systematic review and meta-analysis. *Osteoarthritis Cartilage* 2016;24:1697-707.
- Noble J, Hamblen DL. The pathology of the degenerate meniscus lesion. *J Bone Joint Surg Br* 1975;57:180-6.
- Iwano T, Kurosawa H, Tokuyama H, et al. Roentgenographic and clinical findings of patellofemoral osteoarthrosis. With special reference to its relationship to femorotibial osteoarthrosis and etiologic factors. *Clin Orthop Relat Res* 1990:190-7.
- Dejour D, Allain J. Histoire naturelle de l'arthrose fémoro-patellaire isolée. *Rev Chir Orthop Reparatrice Appar Mot* 2004;90:89-93.
- Mont MA, Haas S, Mullick T, et al. Total knee arthroplasty for patellofemoral arthritis. *J Bone Joint Surg Am* 2002;84-A:1977-81.
- Thompson NW, Ruiz AL, Breslin E, et al. Total knee arthroplasty without patellar resurfacing in isolated patellofemoral osteoarthritis. *J Arthroplasty* 2001;16:607-12.
- Feucht MJ, Cotic M, Beitzel K, et al. A matched-pair comparison of inlay and onlay trochlear designs for patellofemoral arthroplasty: no differences in clinical outcome but less progression of osteoarthritis with inlay designs. *Knee Surg Sports Traumatol Arthrosc* 2015. [Epub ahead of print].
- Stefanik JJ, Zumwalt AC, Segal NA, et al. Association between measures of patella height, morphologic features of the trochlea, and patellofemoral joint alignment: the MOST study. *Clin Orthop Relat Res* 2013;471:2641-8.
- Halai M, Ker A, Anthony I, et al. Femoro Patella Vialla patellofemoral arthroplasty: An independent assessment of outcomes at minimum 2-year follow-up. *World J Orthop* 2016;7:487-93.
- Kalichman L, Zhang Y, Niu J, et al. The association between patellar alignment and patellofemoral joint osteoarthritis features--an MRI study. *Rheumatology (Oxford)* 2007;46:1303-8.
- Dejour D, Reynaud P, Le Coultre B. Douleurs et Instabilité rotulienne. *Essai de Classification. Med Hyg* 1998;56:1466-71.
- Wiberg G. Roentgenographic and anatomic studies on the femoro-patellar joint. *Acta Orthop Scand* 1941;12:319-410.
- Conchie H, Clark D, Metcalfe A, et al. Adolescent knee pain and patellar dislocations are associated with patellofemoral osteoarthritis in adulthood: A case control study. *Knee* 2016;23:708-11.
- Sanders TL, Pareek A, Johnson NR, et al. Patellofemoral Arthritis After Lateral Patellar Dislocation: A Matched Population-Based Analysis. *Am J Sports Med* 2017;45:1012-7.
- Abdul-Hadi O, Parvizi J, Austin MS, et al. Nonsteroidal anti-inflammatory drugs in orthopaedics. *J Bone Joint Surg Am* 2009;91:2020-7.
- Clarke S, Lock V, Duddy J, et al. Intra-articular hylan G-F 20 (Synvisc) in the management of patellofemoral osteoarthritis of the knee (POAK). *Knee* 2005;12:57-62.
- Amin S, Baker K, Niu J, et al. Quadriceps strength and the risk of cartilage loss and symptom progression in knee osteoarthritis. *Arthritis Rheum* 2009;60:189-98.
- Conrozier T, Mathieu P, Schott AM, et al. Factors predicting long-term efficacy of Hylan GF-20 viscosupplementation in knee osteoarthritis. *Joint Bone Spine* 2003;70:128-33.
- Aderinto J, Cobb AG. Lateral release for patellofemoral arthritis. *Arthroscopy* 2002;18:399-403.
- Fulkerson JP, Becker GJ, Meaney JA, et al. Anteromedial tibial tubercle transfer without bone graft. *Am J Sports Med* 1990;18:490-6.
- Kanazawa H, Maruyama Y, Shitoto K, et al. Survival and clinical results of a modified "crosse de hockey" procedure for chronic isolated patellofemoral joint osteoarthritis:

- mid-term follow-up. *J Orthop Traumatol* 2017;18:23-30.
25. Schüttler S, Andjelkov N. Periosteal Transplantation Combined with the Autologous Matrix-Induced Chondrogenesis (AMIC) Technique in Isolated Patellofemoral Osteoarthritis: A Case Report. *Cartilage* 2012;3:194-8.
 26. Asopa V, Willis-Owen C, Keene G. Patellectomy for osteoarthritis: a new tension preserving surgical technique to reconstruct the extensor mechanism with retrospective review of long-term follow-up. *J Orthop Surg Res* 2015;10:107.
 27. Dahm DL, Kalisvaart MM, Stuart MJ, et al. Patellofemoral arthroplasty: outcomes and factors associated with early progression of tibiofemoral arthritis. *Knee Surg Sports Traumatol Arthrosc* 2014;22:2554-9.
 28. Hoogervorst P, de Jong RJ, Hannink G, et al. A 21% conversion rate to total knee arthroplasty of a first-generation patellofemoral prosthesis at a mean follow-up of 9.7 years. *Int Orthop* 2015;39:1857-64.
 29. Argenson JN, Flecher X, Parratte S, et al. Patellofemoral arthroplasty: an update. *Clin Orthop Relat Res* 2005;440:50-3.
 30. Odumenya M, Costa ML, Parsons N, et al. The Avon patellofemoral joint replacement: Five-year results from an independent centre. *J Bone Joint Surg Br* 2010;92:56-60.
 31. Odumenya M, McGuinness K, Achten J, et al. The Warwick patellofemoral arthroplasty trial: a randomised clinical trial of total knee arthroplasty versus patellofemoral arthroplasty in patients with severe arthritis of the patellofemoral joint. *BMC Musculoskelet Disord* 2011;12:265.
 32. Dahm DL, Al-Rayashi W, Dajani K, et al. Patellofemoral arthroplasty versus total knee arthroplasty in patients with isolated patellofemoral osteoarthritis. *Am J Orthop (Belle Mead NJ)* 2010;39:487-91.
 33. McKeever DC. Patellar prosthesis. *J Bone Joint Surg Am* 1955;37-A:1074-84.
 34. Levitt RL. A long-term evaluation of patellar prostheses. *Clin Orthop Relat Res* 1973;(97):153-7.
 35. Vermeulen H, De Doncker E, Watillon M. The Mac Keever patellar prosthesis in femoro-patellar arthrosis. *Acta Orthop Belg* 1973;39:79-90.
 36. De Cloedt P, Legaye J, Lokietek W. Femoro-patellar prosthesis. A retrospective study of 45 consecutive cases with a follow-up of 3-12 years. *Acta Orthop Belg* 1999;65:170-5.
 37. Hanslik L. Patellofemoral sliding bearing in total knee prosthesis. Preliminary report on the implantation of a modified McKeever endoprosthesis combined with Young's alloarthroplasty. *Z Orthop Ihre Grenzgeb* 1971;109:435-40.
 38. Lonner JH. Patellofemoral arthroplasty. *Orthopedics* 2010;33:653.
 39. Krajca-Radcliffe JB, Coker TP. Patellofemoral arthroplasty. A 2- to 18-year followup study. *Clin Orthop Relat Res* 1996:143-51.
 40. Lonner JH. Patellofemoral arthroplasty: the impact of design on outcomes. *Orthop Clin North Am* 2008;39:347-54, vi.
 41. van Jonbergen HP, Poolman RW, van Kampen A. Isolated patellofemoral osteoarthritis. *Acta Orthop* 2010;81:199-205.
 42. Borus T, Brillhault J, Confalonieri N, et al. Patellofemoral joint replacement, an evolving concept. *Knee* 2014;21 Suppl 1:S47-50.
 43. Kazarian GS, Tarity TD, Hansen EN, et al. Significant Functional Improvement at 2 Years After Isolated Patellofemoral Arthroplasty With an Onlay Trochlear Implant, But Low Mental Health Scores Predispose to Dissatisfaction. *J Arthroplasty* 2016;31:389-94.
 44. Leadbetter WB, Mont MA. Patellofemoral arthroplasty: a useful option for recalcitrant symptomatic patellofemoral arthritis. *Semin Arthro* 2009;20:148-60.
 45. Blazina ME, Fox JM, Del Pizzo W, et al. Patellofemoral replacement. *Clin Orthop Relat Res* 1979;(144):98-102.
 46. Kooijman HJ, Driessen AP, van Horn JR. Long-term results of patellofemoral arthroplasty. A report of 56 arthroplasties with 17 years of follow-up. *J Bone Joint Surg Br* 2003;85:836-40.
 47. Cartier P, Sanouiller JL, Khefacha A. Long-term results with the first patellofemoral prosthesis. *Clin Orthop Relat Res* 2005;(436):47-54.
 48. Tauro B, Ackroyd CE, Newman JH, et al. The Lubinus patellofemoral arthroplasty. A five- to ten-year prospective study. *J Bone Joint Surg Br* 2001;83:696-701.
 49. Lonner JH. Patellofemoral arthroplasty: pros, cons, and design considerations. *Clin Orthop Relat Res* 2004;(428):158-65.
 50. Laursen JO. High mid-term revision rate after treatment of large, full-thickness cartilage lesions and OA in the patellofemoral joint using a large inlay resurfacing prosthesis: HemiCAP-Wave(R). *Knee Surg Sports Traumatol Arthrosc* 2016. [Epub ahead of print].
 51. Ackroyd CE, Newman JH, Evans R, et al. The Avon patellofemoral arthroplasty: five-year survivorship and functional results. *J Bone Joint Surg Br* 2007;89:310-5.
 52. Mont MA, Johnson AJ, Naziri Q, et al. Patellofemoral

- arthroplasty: 7-year mean follow-up. *J Arthroplasty* 2012;27:358-61.
53. Al-Hadithy N, Patel R, Navadgi B, et al. Mid-term results of the FPV patellofemoral joint replacement. *Knee* 2014;21:138-41.
 54. Sarda PK, Shetty A, Maheswaran SS. Medium term results of Avon patellofemoral joint replacement. *Indian J Orthop* 2011;45:439-44.
 55. Konan S, Haddad FS. Midterm Outcome of Avon Patellofemoral Arthroplasty for Posttraumatic Unicompartamental Osteoarthritis. *J Arthroplasty* 2016;31:2657-9.
 56. Vandenneucker H, Labey L, Vander Sloten J, et al. Isolated patellofemoral arthroplasty reproduces natural patellofemoral joint kinematics when the patella is resurfaced. *Knee Surg Sports Traumatol Arthrosc* 2016;24:3668-77.
 57. Cotic M, Forkel P, Imhoff AB. Patellofemoral arthroplasty. *Oper Orthop Traumatol* 2017;29:40-50.
 58. Provencher M, Ghodadra NS, Verma NN, et al. Patellofemoral kinematics after limited resurfacing of the trochlea. *J Knee Surg* 2009;22:310-6.
 59. Davidson PA, Rivenburgh D. Focal anatomic patellofemoral inlay resurfacing: theoretic basis, surgical technique, and case reports. *Orthop Clin North Am* 2008;39:337-46.
 60. Leadbetter WB, Seyler TM, Ragland PS, et al. Indications, contraindications, and pitfalls of patellofemoral arthroplasty. *J Bone Joint Surg Am* 2006;88 Suppl 4:122-37.
 61. Heyse TJ, El-Zayat BF, De Corte R, et al. Biomechanics of medial unicondylar in combination with patellofemoral knee arthroplasty. *Knee* 2014;21 Suppl 1:S3-9.
 62. Romagnoli S, Marullo M, Massaro M, et al. Bi-unicompartamental and combined uni plus patellofemoral replacement: indications and surgical technique. *Joints* 2015;3:42-8.
 63. Benazzo F, Rossi SM, Ghiara M. Partial knee arthroplasty: patellofemoral arthroplasty and combined unicompartamental and patellofemoral arthroplasty implants--general considerations and indications, technique and clinical experience. *Knee* 2014;21 Suppl 1:S43-6.
 64. Sabatini L, Schiro M, Atzori F, et al. Patellofemoral Joint Arthroplasty: Our Experience in Isolated Patellofemoral and Bicompartamental Arthritic Knees. *Clin Med Insights Arthritis Musculoskelet Disord* 2016;9:189-93.
 65. Laskin RS, van Steijn M. Total knee replacement for patients with patellofemoral arthritis. *Clin Orthop Relat Res* 1999;89-95.
 66. Parvizi J, Stuart MJ, Pagnano MW, et al. Total knee arthroplasty in patients with isolated patellofemoral arthritis. *Clin Orthop Relat Res* 2001;(392):147-52.
 67. Dalury DF. Total knee replacement for patellofemoral disease. *J Knee Surg* 2005;18:274-7.
 68. Meding JB, Wing JT, Keating EM, et al. Total knee arthroplasty for isolated patellofemoral arthritis in younger patients. *Clin Orthop Relat Res* 2007;464:78-82.
 69. van der List JP, Chawla H, Villa JC, et al. Why do patellofemoral arthroplasties fail today? A systematic review. *Knee* 2017;24:2-8.
 70. Davies AP. High early revision rate with the FPV patello-femoral unicompartamental arthroplasty. *Knee* 2013;20:482-4.
 71. Baker PN, Refaie R, Gregg P, et al. Revision following patello-femoral arthroplasty. *Knee Surg Sports Traumatol Arthrosc* 2012;20:2047-53.
 72. Annual Report 2014 Australian Hip and Knee Arthroplasty Register. Australian Orthopaedic Association National Joint Replacement Registry 2014.
 73. Nicol SG, Loveridge JM, Weale AE, et al. Arthritis progression after patellofemoral joint replacement. *Knee* 2006;13:290-5.
 74. Monk AP, van Duren BH, Pandit H, et al. In vivo sagittal plane kinematics of the FPV patellofemoral replacement. *Knee Surg Sports Traumatol Arthrosc* 2012;20:1104-9.
 75. Parratte S, Lunebourg A, Ollivier M, et al. Are revisions of patellofemoral arthroplasties more like primary or revision TKAs. *Clin Orthop Relat Res* 2015;473:213-9.

doi: 10.21037/aoj.2017.07.09

Cite this article as: Berruto M, Tradati D, Ferrua P, Maione A, Usellini E. Patellofemoral knee arthroplasty. *Ann Joint* 2017;2:48.